Vanda Pharmaceuticals | VNDA - Efectivo Y Equivalentes





Efectivo Y Equivalentes Cambio Fecha
Acadia Pharmaceuticals USD 819.69M 27.33M 2025-12
Agios Pharmaceuticals USD 89.13M 3.58M 2025-12
Akebia Therapeutics USD 184.84M 18.4M 2025-12
Alnylam Pharmaceuticals USD 1.66B 167M 2025-12
Anika Therapeutics USD 57.99M 4.82M 2025-09
Arrowhead Research USD 201.64M 112.94M 2025-12
AstraZeneca USD 8.14B 1.08B 2025-09
Bristol-Myers Squibb USD 10.21B 5.52B 2025-12
Eli Lilly USD 7.27B 2.52B 2025-12
Enanta Pharmaceuticals USD 37.44M 5.14M 2025-12
Esperion Therapeutics USD 92.45M 6.39M 2025-09
Halozyme Therapeutics USD 133.82M 285.84M 2025-12
Heron Therapeutics USD 43.07M 26.55M 2025-09
Insmed USD 510.44M 175.68M 2025-12
J&J USD 19.71B 1.48B 2025-12
Lexicon Pharmaceuticals USD 21.36M 41.52M 2025-06
Ligand Pharmaceuticals USD 174.93M 489.59M 2025-12
Merck USD 18.17B 10.16B 2025-09
Minerva Neurosciences USD 12.29M 2.96M 2025-09
Moderna USD 2.6B 1.46B 2025-12
Novartis USD 9.56B 2.9B 2025-09
Pfizer USD 1.34B 295M 2025-09
PTC Therapeutics USD 984.65M 312.03M 2025-12
Puma Biotechnology USD 53.52M 1.14M 2025-09
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Sanofi EUR 7.66B 1.25B 2025-12
Takeda JPY 654.94B 26.55B 2025-12
Teva Pharmaceutical Industries USD 3.56B 1.35B 2025-12
Ultragenyx Pharmaceutical USD 202.51M 36.4M 2025-09
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12
Veracyte USD 362.58M 47M 2025-12